Francesca DeMartino

OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ.

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark.

Macrocure Ltd. is a clinical-stage biotechnology company, which engages in the development and commercialization of advanced cell therapy products. Its product, CureXcell, is an advanced wound care therapy that treat such wounds by injecting living human white blood cells that have been activate to facilitate the healing process. The company was founded by David Ben-Ami on January 14, 2008 and is headquartered in Petach Tikva, Israel.